Loading
A phase 2 trial of Domvanalimab, Quemliclustat, Zimberelimab and Oxaliplatin in advanced solid tumours, run by Arcus Biosciences, Inc., active and no longer recruiting.
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies is a phase 2 interventional study registered as NCT05329766 by Arcus Biosciences, Inc., with 332 participants enrolled, started 2022-06-10 and due to reach its primary completion in 2027-01. Interventions recorded: Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin and Oxaliplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zimberelimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Zimberelimab, Gilead Sciences (incl. Kite) and the tag pipeline.
Shares Oxaliplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/